Insider Buying: CTI BioPharma Corp (CTIC) Insider Purchases 6,333,333 Shares of Stock

CTI BioPharma Corp (NASDAQ:CTIC) insider Value Fund L. P. Biotechnology acquired 6,333,333 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were acquired at an average cost of $3.00 per share, for a total transaction of $18,999,999.00. The acquisition was disclosed in a filing with the SEC, which is available through this link.

CTI BioPharma Corp (CTIC) traded up $0.11 on Monday, reaching $3.32. The company’s stock had a trading volume of 633,711 shares, compared to its average volume of 424,768. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.19. The stock has a market capitalization of $142.65, a P/E ratio of -3.22 and a beta of 0.50. CTI BioPharma Corp has a one year low of $2.45 and a one year high of $4.90.

Separately, Zacks Investment Research raised CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Wednesday, December 27th.

A hedge fund recently bought a new stake in CTI BioPharma stock. JPMorgan Chase & Co. bought a new position in shares of CTI BioPharma Corp (NASDAQ:CTIC) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 85,448 shares of the biopharmaceutical company’s stock, valued at approximately $272,000. JPMorgan Chase & Co. owned approximately 0.20% of CTI BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). 42.84% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Insider Buying: CTI BioPharma Corp (CTIC) Insider Purchases 6,333,333 Shares of Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at

About CTI BioPharma

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with's FREE daily email newsletter.

Leave a Reply